Drugs / BTI-410
BTI-410
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01933256 | Aug 2013 → Sep 2014 | type 2 diabetes mellitus | CureDM | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01638611 Comparator | Jul → Sep 2012 | — | CureDM | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BTI-410 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297978 ↗ |
| Known as | HIP2B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01933256 ↗ |
| Known as | Human proislet peptide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297978 ↗ |
| Known as | Pancreate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297978 ↗ |
| Known as | Proisletide acetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297978 ↗ |
| Modality | Peptide | “HIP2B is the stabilized form of the Human proIslet Peptide (HIP).” NCT01638611 ↗ |
| Route | Subcutaneous | “Repeated Subcutaneous Doses of HIP2B” NCT01933256 ↗ |